The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | The evolution of myelofibrosis treatment and modern-day management
John Mascarenhas, MD, Mount Sinai, New York, NY, talks on the evolution of myelofibrosis treatment, highlighting recent advances. In particular, Prof. Mascarenhas talks on disease heterogeneity and the need for personalized approaches. Prof. Mascarenhas also gives an overview of the use of the JAK inhibitors ruxolitinib and fedratinib, and comments on the need for anemia-directed therapies. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
John Mascarenhas, MD, has received institutional research support from Incyte, Novartis, Merck, Kartos, PharmaEssentia, Forbius, Roche and CTI BIO; and has received consultancy fees from Incyte, BMS, Roche, Sierra Oncology, PharmaEssentia, CTI bio, Constellation and Kartos.
